

ASX ANNOUNCEMENT

7 May 2025

Investor webinar invitation

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to invite shareholders to attend an investor webinar presentation to be held:

Time: 10am AWST / 12pm AEST

Date: Tuesday 13th May 2025



The presentation will be delivered by Managing Director Paul Long and provide an overview of the LGP's March quarterly results, with the Company reporting revenue of \$36.6m (unaudited) for FY25 representing 40% growth from the prior year. LGP also reported \$9.6m in revenue (unaudited) for the March quarter and a record month of \$4 million (unaudited) in March.

In addition, Mr Long will provide an update on LGP's operational activities, including the acquisition of Australian medicinal cannabis distribution business, Health House, which generated \$0.8 million in third-party product sales in the two months post acquisition. Meanwhile, LGP has continued to accelerate its expansion into lucrative European and UK markets.

The webinar will be held via Zoom and will provide attendees the opportunity to submit questions via a moderated Q&A session following the formal presentation.

To register for the webinar, please visit:

https://us02web.zoom.us/webinar/register/WN_WRnHBZ56RmGXlr80YoHxRA

A recorded copy of the webinar will be made available on Little Green Pharma's website following the event.



ENDS
APPROVED FOR RELEASE



Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

David Tasker
Managing Director
Chapter One Advisors
E: dtasker@chapteroneadvisors.com.au
T: +61 433 112 936

About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com and
Reset Mind Sciences: <https://www.resetmind.com.au/>

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.investorcentre.com/au

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>